MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/bios16050289

Медицинская библиотека · Biosensors · 2026

Glycemic Efficacy and Safety by Using Insulin Degludec and Aspart Guided by a Clinical Decision Support System in Non-Critically Ill Inpatients with Type 2 Diabetes Mellitus.

Aberer Felix, Hochfellner Daniel A, Baumann Petra M, Höll Bernhard, Beck Peter, Pieber Thomas R, Mader Julia K

СтатьяПеревод пока не подготовлен

Аннотация

Background

Algorithm-based insulin dosing systems are increasingly used in hospitals and have shown the potential to efficiently and safely enable glycemic control. The goal of this study was to evaluate glycemic control using the ultralong-acting basal insulin degludec (IDeg) in combination with insulin aspart (IAsp) within an algorithm-driven electronic clinical decision support system (cDSS) in inpatients with type 2 diabetes (T2D).

Methods

In this non-controlled single-arm pilot study, an electronic, algorithm-based cDSS was applied for the management of insulin treatment in an internal general ward. Thirty hospitalized patients with T2D (18 female, age 74.1 ± 10.9 years, HbA1c 72.4 ± 22.3 mmol/mol, BMI 28.6 ± 5.6 kg/m2, diabetes duration 13.2 ± 11.6 years, creatinine 1.5 ± 1.2 mg/dL, length of hospital stay 9.1 ± 4.0 days) were included in the study. Capillary blood glucose (BG) was evaluated four times daily using a point-of-care device integrated into the hospital information system. In addition, all participants received a blinded continuous glucose monitoring (CGM; Abbott Freestyle Libre Pro) system. The primary endpoint was defined as the percentage of BG measurements within the target range of 3.9-7.8 mmol/L.

Results

Overall, 722 BG values and 17,242 CGM data points were available. Of those, 52.2% and 55.0% were in the specified target area (3.9-7.8 mmol/L), respectively. Mean BG prior to study start was 11.9 ± 4.4 mmol/L and improved to 7.5 ± 1.9 mmol/L and 7.4 ± 1.4 mmol/L after 6 and 10 days of treatment. BG < 3.9, <3.0 and <2.2 mmol/L was 1.25%, 0.28% and 0%, respectively. Adherence to the total daily insulin dose suggested by the cDSS was 94.2%, and 99.5% of all basal and 85.3% of all bolus insulin suggestions were accepted by the nurses in charge. Basal-bolus therapy using the cDSS covered 85% of the participants' total hospital stay.

Conclusions

Glycemic control using IDeg within an algorithm-driven cDSS could effectively and safely be achieved in the hospital and was highly accepted.

Для цитирования: Aberer Felix, Hochfellner Daniel A, Baumann Petra M, Höll Bernhard, Beck Peter, Pieber Thomas R, Mader Julia K. Glycemic Efficacy and Safety by Using Insulin Degludec and Aspart Guided by a Clinical Decision Support System in Non-Critically Ill Inpatients with Type 2 Diabetes Mellitus.. Biosensors. 2026. DOI: 10.3390/bios16050289.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.